



## Astria Therapeutics to Present at Upcoming Investor Conferences

September 10, 2021

BOSTON--([BUSINESS WIRE](#))--[Astria Therapeutics, Inc.](#) (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on lead program STAR-0215 at the following upcoming virtual investor conferences:

- H.C. Wainwright 23<sup>rd</sup> Annual Global Investment Conference on September 13, 2021. The on-demand presentation will be available at 7:00am ET at the following link: <https://journey.ct.events/view/5b3d4715-8ae5-4b39-9000-ba72d0444848>
- Oppenheimer Fall Healthcare, Life Sciences, and MedTech Summit on September 22, 2021. The presentation will be available at 2:55pm ET at the following link: <https://wsw.com/webcast/oppenheimer16/catb/2735278>

Webcasts of the events can be accessed from the investors section of [www.astriatx.com](http://www.astriatx.com). Archived replays will be available for 30 days following the event.

### About Astria Therapeutics:

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Learn more about our company on our website, [www.astriatx.com](http://www.astriatx.com), or follow us on Twitter and Instagram @AstriaTx and on Facebook and LinkedIn.

### Contacts

Astria:

#### Investor relations:

Andrea Matthews

[investors@astriatx.com](mailto:investors@astriatx.com)

#### Media:

Elizabeth Higgins

[media@astriatx.com](mailto:media@astriatx.com)